ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1098

Safety and Efficacy Of Influenza Vaccination In Patients Suffering From Fibromyalgia

Jacob N. Ablin1, Valerie Aloush1, Ayelet Brill2, Mark Berman3, Merav Barzilai4, Dan Caspi1, Michal Mandelboim5, David Levartovsky6, Ari Polachek7, Yonatan Wolman1, Daphna Paran8, Michael Barkagan4 and Ori Elkayam9, 1Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2Department of Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3Internal Medicine F, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4Internal Medicine 6, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 5Central Virology Laboratory, Sheba Medical Center, Ramat Gan, Israel, 6Rheumatology, Tel Aviv Medical Ctr, Tel Aviv, Israel, 7Rheumatology, Tel Aviv Medical Center, Tel Aviv, Israel, 8Rheumatology, Tel Aviv Sourasky Medical Ctr, Tel-Aviv university, Tel Aviv, Israel, 9Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fibromyalgia and vaccines

  • Tweet
  • Email
  • Print
Session Information

Session Title: Fibromyalgia, Soft Tissue Disorders and Pain II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Fibromyalgia syndrome (FMS) is considered to result from exposure of a genetically susceptible individual to various “triggers” including physical trauma, stress etc. Viral infections have also been linked to FMS etiology. A possible role of vaccination in  FMS etiology has been raised. Gulf war syndrome, an entity with considerable clinical overlap with FMS, has been linked with exposure to multiple vaccinations. The possibility that vaccination – related adjuvants induce a multisystem disorder characterized by symptoms such as fatigue, cognitive impairment and arthralgia has also been raised.In view of this background, the aim of the current study was to evaluate the efficacy and safety of influenza vaccination in FMS patients.

Methods:

Patients (19) were recruited at a specialized FMS clinic. After informed consent, patients underwent physical and dolorimetric examination and fulfillment of ACR 1990 FMS classification criteria was documented. Patients answered the Fibromyalgia Impact Questionnaire (FIQ) as well as the widespread pain index (WPI) and Symptoms severity scale (SSS) – components of the 2010 diagnostic criteria. 38 Healthy subjects were recruited as controls. All participants were vaccinated with inactivated split virion influenza vaccine, recommended by the WHO and serum was collected for antibody titer determination.

Six weeks after vaccination, patients were re-evaluated. Sera were tested by Haemagglutination (HI) against the three antigens included in the vaccine: A/California (H1N1), A/Perth (H3N2) and B/Brisbane. Humoral response was defined as either a fourfold or more rise in titer, or a rise from a non-protective baseline level of <1/40 to 1/40. Geometric mean titers of antibodies were calculated.

Results:

No severe vaccination reactions were observed. As shown in the table, no significant change was observed between WPI, SSS and FIQ values before and after vaccination, indicating no worsening of FMS symptoms.

FMS  patients (n=19)

Pre-Vaccination

Post-vaccination

P value

WPI (SD)

13.3(4.7)

11(5.4)

0.19

SSS (SD)

9.1(1.6)

9.0(2.7)

0.88

FIQ (SD)

67.3(14.2)

65.9(22.0)

0.82

Vaccine immunogenicity: Six weeks after vaccination, FMS patients displayed significant increases in geometric mean titers of HI antibody against H1N1 and B/Bri viruses: from 29.9 to 387.9 (p=0.0011), from 82.9 to 460.9 (p=0.0007)  and from 28.8 to 96.0 (p=0.08) respectively. The rates of sero-protection (defined as antibody levels above 1/40) increased from 22.9% for H1N1 to 89.5% post vaccination. Significant increase in HI antibody titers were also demonstrated among healthy controls: H1N1 (p=0.000435), B/Bri (p=0.000331) and Perth (p=0.004953). 

Conclusion:

Influenza vaccination was both safe and effective in FMS patients. Neither severe adverse reactions nor significant worsening of FMS symptoms were recorded following vaccination and serological evidence of sero-conversion was observed, similar to healthy controls. In view of these results, FMS patients should be encouraged to undergo influenza vaccination according to standard WHO recommendations.


Disclosure:

J. N. Ablin,

Pfizer Inc,

8;

V. Aloush,
None;

A. Brill,
None;

M. Berman,
None;

M. Barzilai,
None;

D. Caspi,
None;

M. Mandelboim,
None;

D. Levartovsky,
None;

A. Polachek,
None;

Y. Wolman,
None;

D. Paran,
None;

M. Barkagan,
None;

O. Elkayam,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-influenza-vaccination-in-patients-suffering-from-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies